Scientific Foundation
The Science Behind ScudoMind
NAI therapy engages five distinct neuropathways simultaneously. This multi-pathway engagement explains both the speed and the breadth of the antidepressant effect observed in clinical evidence.
Key Neuropathways
| Biological Pathway | Key Mechanism & Evidence | Relevance to Antidepressant Effect |
|---|---|---|
| Neuroendocrine Regulation | Attenuates HPA axis hyperactivity by reducing stress-induced corticosterone elevation. | Normalizes the stress response — a core physiological dysfunction in depression. |
| Autonomic Nervous System | Enhances parasympathetic tone (increased HRV) and modulates sympatho-vagal balance via vagal nerve and hypothalamic pathways. | Reduces physiological hyperarousal and promotes somatic recovery and relaxation. |
| Neurotransmitter Modulation | Modulates serotonin (5-HT) levels and accelerates enzymatic oxidation via superoxide pathways. | Modulates monoaminergic signaling systems central to mood regulation. |
| Immunomodulation & Antioxidative | Rebalances Th1/Th2 cytokine profiles, downregulates pro-inflammatory cytokines and Reactive Oxygen Species (ROS) pathways. | Targets the inflammatory hypothesis of depression by reducing neuroinflammation and oxidative stress. |
| Emotional & Cognitive Processing | Increases positive emotional processing, improves vigilance and memory for positive stimuli, and enhances cognitive performance. | Mimics early cognitive shifts seen with conventional antidepressants, reversing negative cognitive bias. |
Results based on multiple small-scale trials including a landmark randomized controlled trial (Goel et al., 2005).
Treatment Comparison
ScudoMind's approach compares favorably to every established alternative on efficacy, tolerability, and cost.
| Treatment | Treatment Setting | Response Rate | Remission Rate | Time to Response | Side Effects | Reimbursement Cost |
|---|---|---|---|---|---|---|
| ScudoMind | Daily · Home or On-the-Go | 51% | 50% | 5 weeks | None reported | €2,750 |
| ECT | Clinic · 3×/week | ~54% | 31–47% | 6–8 weeks | Cognitive & memory loss | €13,500–€23,000 |
| TMS | Clinic · 5×/week | ~50% | 31–37% | 4–6 weeks | Headache | €5,500–€13,500 |
| Neuromodulation Wearable | Daily at home · 2×/day | 50–60% | Up to 50% | 8–16 weeks | Very mild | €3,600 |
| Esketamine | Clinic · 1–2×/week | ~50% | 30–50% | 4–12 weeks | Dissociation, hypertension | €5,500–€18,000 |
Results based on multiple small-scale trials including a landmark randomized controlled trial (Goel et al., 2005).